Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights

Citius Pharmaceuticals, Inc.

Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.
Cash & equivalents $3.3M; plans to raise additional capital.
R&D expense $11.9M, G&A $18.2M; stock-based compensation $11.8M.
FDA approved LYMPHIR (denileukin diftitox-cxdl) for CTCL; commercial launch expected H1 2025.
Completed Citius Oncology spin-off (CTOR) on Nasdaq in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.